[针对真多细胞血症的干扰素治疗]
1Department of Hematology, Juntendo University School of Medicine.
干扰素 (IFN) 在治疗骨髓增殖性瘤 (MPNs) 中表现有前途,如真多细胞血症 (PV). 一种新的形式,rope-interferon alfa-2b,在日本PV患者中显示出有效性和耐受性,为未来的治疗提供了希望.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 干扰素 (IFN) 在治疗骨髓增殖性瘤 (MPNs) 中有着悠久的历史.
- 毒性和耐受性问题限制了传统的IFN使用.
- 基化IFN和新型配方,如rope-interferon alfa-2b,重新引起了对治疗MPN的IFN治疗的兴趣.
研究的目的:
- 评估Ropeginterferon alfa-2b在日本多细胞真血病 (PV) 患者的疗效,安全性和耐受性.
- 评估rope-interferon alfa-2b作为日本PV未来治疗选择的潜力.
主要方法:
- 进行了2期临床研究.
- 被诊断为PV的日本患者被纳入.
- 治疗涉及rope-interferon alfa-2b,并评估了疗效,安全性和耐受性.
主要成果:
- 这项研究表明,在日本的PV患者中,rope-interferon alfa-2b的疗效.
- 观察到有利的安全性和耐受性概况.
- 显示出持久的血液学和分子反应.
结论:
- 在日本,ropeinterferon alfa-2b在治疗多细胞血病方面显示出显著的前景.
- 药物的有效性,安全性和耐受性支持其潜在的批准和使用.
- 这为改善日本光伏患者管理提供了希望.
更多相关视频
09:11Zika Virus Infectious Cell Culture System and the In Vitro Prophylactic Effect of Interferons
Published on: August 23, 2016
08:26Development and Validation of an Ultrasensitive Single Molecule Array Digital Enzyme-linked Immunosorbent Assay for Human Interferon-α
Published on: June 14, 2018
相关概念视频
Venous Thrombosis III: Interprofessional Care
Tumor Immunotherapy
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Peripheral Artery Disease III: Interprofessional Care
